Clinical Experience with A Novel Large Bore Vascular Closure Device After Transfemoral TAVR
DOI: 10.4244/EIJ-D-19-00523
Hendrik Ruge1,; Magdalena Erlebach2, ; Patrick Mayr3, ; Sabine Bleiziffer4, ; Rüdiger Lange5, ;
1. INSURE (Institute for Translational Cardiac Surgery), Department of Cardiovascular Surgery, German Heart Center, TUM, Munich, Germany; German Heart Center Munich, Department of Cardiovascular Surgery, TUM, Munich, Germany, Germany 2. INSURE (Institute for Translational Cardiac Surgery),Department of Cardiovascular Surgery,German Heart Center,TUM, Munich,Germany; German Heart Center Munich,Department of Cardiovascular Surgery,TUM,Munich,Germany 3. German Heart Center Munich,Department of Anaesthesiology,German Heart Center,TUM,Munich,Germany 4. Clinic for Thoracic and Cardiovascular Surgery,Heart and Diabetes Center NRW,Bad Oeynhausen,Germany 5. INSURE (Institute for Translational Cardiac Surgery),Department of Cardiovascular Surgery,German Heart Center,TUM, Munich,Germany; German Heart Center Munich,Department of Cardiovascular Surgery,TUM,Munich,Germany
Disclaimer:
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention -
has been published immediately upon acceptance as it was received. The content of this article is the sole
responsibility of the authors, and not that of the journal or its publishers.
To read the full content of this article, please log in to download the PDF.
Utilization of TAVR is increasing. Vascular complications after transfemoral TAVR are still of concern. The majority is related to the large bore puncture site[1]. Currently, large bore arteriotomy closure relies on suture-based techniques, such as the Perclose Proglide® or Prostar XL® devices(Abbott, Redwood City, USA). Closure devices such as MANTA®(Teleflex, Morrisville, North Carolina) or PerQSeal®(Vivasure Medical, Galway, Ireland) designed to seal large bore arteriotomies became recently available. The novel InClosure®-VCD(InSeal Medical, Caesarea, Israel) provides hemostasis using a flexible intravascular biodegradable membrane supported by a nitinol frame (Figure 1). We report our single-center experience using the novel VCD.
